7th November 2016
Innovative biotechnology company, Axim Biotechnologies Inc has appointed Grayling in the US to support its Investor Relations and Public Relations’ needs.
Axim Biotechnologies is engaged in the research and development, and production of pharmaceutical, nutriceutical and cosmetic products, as well as the procurement of genetically and nano-controlled active ingredients. The company’s particular focus is on the development of treatments for pain, spasticity, anxiety and other medical disorders using cannabinoids-based products. Pharmaceutical R&D aims to deliver systems and active pharmaceutical ingredients for treating conditions such as Parkinson's disease, Alzheimer's disease, restless leg syndrome and Crohn's disease.
Presently, the company is conducting clinical studies of MedChewRx, a pharmaceutical chewing gum containing cannabinoids. The company is in the process of getting FDA and EMA regulatory approval to launch this product in 2017, and it is in regard to this that Grayling is providing support.
Grayling’s efforts will be driven by New York based executive vice president, Lucia Domville. She says: “This is a fascinating company that is really pushing the boundaries with its research, and we are thrilled to be their partner.”
15th April 2019
Grayling New York is growing, with the addition of Niveen Saleh, who joins as an account director. Niveen has five years of experience in tech PR, franchise PR, and employee communications....Read More
10th April 2019
Grayling has been named a finalist in five categories in the prestigious SABRE Awards EMEA. The nominated campaigns were developed by Grayling’s offices in Poland, Russia, Spain and the UK,...Read More
8th April 2019
With just 44 days to go before the EU elections, Grayling Brussels launches today a new online platform with the latest EU elections insights, gossip and trends: www.TheEULobby.eu On...Read More